Abstract
Background
A study using the US FDA Adverse Event Reporting System (FAERS) found significant acute kidney injury (AKI) reporting associations with vancomycin, fluoroquinolones, penicillin combinations, and trimethoprim–sulfamethoxazole. Other antibiotics may also lead to AKI, but no study has systemically compared AKI reporting associations for many available antibiotics.
Objective
The objective of this study was to evaluate the reporting associations between AKI and many available antibiotics using FAERS.
Methods
FAERS reports from 1 January 2015 to 31 December 2017 were included in the study. The Medical Dictionary for Regulatory Activities (MedDRA) was used to identify AKI cases. Reporting odds ratios (RORs) and corresponding 95% confidence intervals (CIs) for the reporting associations between antibiotics and AKI were calculated. A reporting association was considered statistically significant when the lower limit of the 95% CI was > 1.0.
Results
A total of 2,042,801 reports (including 20,138 AKI reports) were considered. Colistin had the greatest proportion of AKI reports, representing 25% of all colistin reports. AKI RORs (95% CI) for antibiotics were, in descending order: colistin 33.10 (21.24–51.56), aminoglycosides 17.41 (14.49–20.90), vancomycin 15.28 (13.82–16.90), trimethoprim–sulfamethoxazole 13.72 (11.94–15.76), penicillin combinations 7.95 (7.09–8.91), clindamycin 6.46 (5.18–8.04), cephalosporins 6.07 (5.23–7.05), daptomycin 6.07 (4.61–7.99), macrolides 3.60 (3.04–4.26), linezolid 3.48 (2.54–4.77), carbapenems 3.31 (2.58–4.25), metronidazole 2.55 (1.94–3.36), tetracyclines 1.73 (1.26–2.36), and fluoroquinolones 1.71 (1.49–1.97).
Conclusion
This study found 14 classes of antibiotics having significant reporting associations with AKI. Among the antibiotics evaluated in this study, colistin had the highest AKI ROR and moxifloxacin had the lowest.
Similar content being viewed by others
Change history
26 June 2020
In the original publication of the article, the second sentence in the figure��2 caption should read as below:
References
Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756–66.
Zeng X, McMahon GM, Brunelli SM, Bates DW, Waikar SS. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol. 2014;9(1):12–20.
Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41(8):1411–23.
Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13(4):241–57.
Linder A, Fjell C, Levin A, Walley KR, Russell JA, Boyd JH. Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill. Am J Respir Crit Care Med. 2014;189(9):1075–81.
Bentley ML, Corwin HL, Dasta J. Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies. Crit Care Med. 2010;38(6 Suppl):S169–74.
Khalili H, Bairami S, Kargar M. Antibiotics induced acute kidney injury: incidence, risk factors, onset time and outcome. Acta Med Iran. 2013;51(12):871–8.
Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL. Vancomycin plus piperacillin–tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46(1):12–20.
Welch HK, Kellum JA, Kane-Gill SL. Drug-associated acute kidney injury identified in the United States Food and Drug Administration Adverse Event Reporting System database. Pharmacotherapy. 2018;38(8):785–93.
Waterer GW, Wunderink RG. Increasing threat of Gram-negative bacteria. Crit Care Med. 2001;29(4 Suppl):N75–81.
Berlana D, Llop JM, Fort E, Badia MB, Jodar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm. 2005;62(1):39–47.
Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22(6):535–43.
Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). https://www.fda.gov/drugs/surveillance/fda-adverse-event-reporting-system-faers. Accessed 26 May 2019.
Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 26 May 2019.
Evoy KE, Teng C, Encarnacion VG, Frescas B, Hakim J, Saklad S, et al. Comparison of quetiapine abuse and misuse reports to the FDA Adverse Event Reporting System with other second-generation antipsychotics. Subst Abuse. 2019;13:1–8.
Teng C, Reveles KR, Obodozie-Ofoegbu OO, Frei CR. Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA Adverse Event Reporting System. Int J Med Sci. 2019;16(5):630–5.
Teng C, Walter EA, Gaspar DK, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System. Int J Med Sci. 2019;16(7):1018–22.
McConeghy KW, Soriano MM, Danziger LH. A quantitative analysis of FDA Adverse Event Reports with oral bisphosphonates and Clostridium difficile. Pharmacotherapy. 2016;36(10):1095–101.
Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–6.
MedDRA MSSO. Introductory Guide for Standardised MedDRA Queries (SMQs) Version 21.0. https://www.meddra.org/sites/default/files/guidance/file/smq_intguide_21_0_english.pdf. Accessed 26 May 2019.
Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–36.
Gai Z, Samodelov SL, Kullak-Ublick GA, Visentin M. Molecular mechanisms of colistin-induced nephrotoxicity. Molecules. 2019;24(3):653.
Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab. 2016;7(3):136–47.
Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43(5):1003–12.
Wan H, Hu Z, Wang J, Zhang S, Yang X, Peng T. Clindamycin-induced kidney diseases: a retrospective analysis of 50 patients. Intern Med. 2016;55(11):1433–7.
Subedi P, Chowdhury A, Tanovic K, Dumic I. Clindamycin: an unusual cause of acute kidney injury. Am J Case Rep. 2019;20:248–51.
Bird ST, Etminan M, Brophy JM, Hartzema AG, Delaney JA. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ. 2013;185(10):E475–82.
Luo K, Lim SW, Jin J, Jin L, Gil HW, Im DS, et al. Cilastatin protects against tacrolimus-induced nephrotoxicity via anti-oxidative and anti-apoptotic properties. BMC Nephrol. 2019;20(1):221.
Acknowledgements
The authors of this study would like to thank Courtney Baus, a Doctor of Pharmacy student at the University of Texas at Austin College of Pharmacy, for her editorial review of this manuscript. No funding was sought for this research study. Dr. Frei was supported in part by a National Institutes of Health Clinical and Translational Science Award (National Center for Advancing Translational Sciences, UL1 TR001120, UL1 TR002645, and TL1 TR002647) while the study was being conducted. Dr. Alvarez received support from the National Institutes of Health (K08DK101602) and Agency for Healthcare Research and Quality (R24HS022418). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs, the National Institutes of Health, or the authors’ affiliated institutions.
Author information
Authors and Affiliations
Contributions
Study concept and design: CT, CRF; Statistical analysis: CT; Interpretation of data: All authors; Drafting of the manuscript: TMP, CT; Critical revision of the manuscript for important intellectual content: All authors; Study supervision: CRF.
Corresponding author
Ethics declarations
Funding
No funding was sought for this research study. Dr. Frei was supported, in part, by a National Institutes of Health Clinical and Translational Science Award (National Center for Advancing Translational Sciences, UL1 TR001120, UL1 TR002645, and TL1 TR002647) while the study was being conducted. Dr. Alvarez received support from the National Institutes of Health (K08DK101602) and Agency for Healthcare Research and Quality (R24HS022418). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Conflict of interest
Taylor M. Patek, Chengwen Teng, Kaitlin E. Kennedy, Carlos A. Alvarez, and Christopher R. Frei have no conflicts of interest that are directly relevant to the content of this study.
Data Sharing Statement
The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Rights and permissions
About this article
Cite this article
Patek, T.M., Teng, C., Kennedy, K.E. et al. Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). Drug Saf 43, 17–22 (2020). https://doi.org/10.1007/s40264-019-00873-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40264-019-00873-8